Connect with us

News

Davina McCall’s menopause documentary will increase demand for support, says expert

Published

on

Davina McCall’s Channel 4 documentary is expected to create an increased demand for employee menopause support, as 88 per cent say the symptoms affect work

Despite the general menopause discussion growing louder, recent research from Peppy, a digital health platform that offers employees access to remote support, has found that 78 per cent of employees with menopause symptoms admit they have not spoken about menopause at work.

However, the company believes that employers should anticipate an increase in demand for workplace menopause support following Davina McCall’s new documentary for Channel 4, The Menopause Brain Drain.

The programme highlights how declining hormone levels during the menopause years can be associated with sudden forgetfulness and a lack of concentration, most-commonly referred to as ‘brain fog’.

Of the 548 respondents to Peppy’s survey of employees experiencing menopausal symptoms, the findings showed that 80 per cent had sleep problems, 78 per cent had brain fog, 73 per cent had anxiety, and 67 per cent had difficulty focusing.

In the same time, 88 per cent of employees said that perimenopause or menopause affected their ability to work.

“Brain fog – and the forgetfulness, self-doubt and imposter syndrome that may come with it – is an issue that workplaces need to take seriously,” says Kathy Abernethy, menopause specialist and director of menopause services at Peppy. “What’s more, brain fog and other symptoms of menopause are not just limited to a short period of people’s lives. They can begin months or even years before periods stop and persist for an average of four years or more.”

“Davina’s recent documentary will undoubtedly give some employees additional confidence about speaking to their employer about how brain fog is impacting their working life,” the expert adds. “Employees need to be prepared, as for some, this will be an enormous step with associated concerns about how they will be perceived going forwards.”

Peppy explains that some employees may forget what they are saying mid-sentence and for others, a seemingly simple task can turn into one that takes much longer than expected. This can create immense stress and anxiety in anticipation of meetings, deadlines and everyday work. Employees may also doubt their ability, value and performance, or consider taking sick days, changing job or leaving the workplace altogether.

Of the employees who had spoken to their employer about their symptoms, 38 per cent asked for flexible working or remote working and 36 per cent asked for support with emotional wellbeing.

“Company-wide training and education is a really important first step in supporting employees with the symptoms of menopause,” Abernethy explains.

“If an employee wants to speak up or ask for help and their line manager’s only knowledge of menopause is hot flushes, it’s not going to be a productive conversation. Employers and managers need to be empowered with the knowledge to confidently have these discussions and crucially, to also understand the pathway of support available.”

Other means to support staff include appointing menopause champions for raising awareness and breaking down stigma, offering confidential, clinically led menopause and wellbeing support and recommending trusted resources for advice.

“Supporting menopausal employees must start with awareness, helping them and those around them understand why they are suffering from brain fog,” Abernethy continues. “The second step is support with how to manage the symptoms, and that requires practical guidance and expert support. Taking these steps will help employers reap the rewards of a happier, healthier and more diverse workforce.”

For more information, visit peppy.health.

Entrepreneur

Just 24 hours left to nominate your company of the year

Published

on

You have until Friday to nominate your femtech company of the year.

The award is one of 10 featuring at Femtech World’s third annual awards event, which attracts entries from across the UK, EU and Europe.

The Company of the Year Award is for companies that have demonstrated exceptional leadership in tackling women’s health needs through groundbreaking products, services or platforms that are shaping the future of global femtech.

If your company is driving innovation, impact and growth in this space, this award was made for you.

About the sponsor: Femovate

The category is backed by Femovate, the global femtech incubator using design to fuel innovation across every stage of a woman’s health journey, from proactive prevention through to personalised treatment.

Femovate has invested over US$2 million in design capital, working side-by-side with founding teams to bring market-ready solutions to life.

The startups it supports have collectively raised US$120 million, launched 30 products, and secured seven FDA clearances.

Why enter?

The Femtech World Awards are free to enter.

Winners and shortlisted companies receive extensive coverage across all Femtech World platforms.

Winners will also receive a trophy and the opportunity to be featured in an interview for the publication.

Find out more about the Femtech World Award and enter here by 4pm BST on Friday 17.

Continue Reading

Diagnosis

Women with osteoporosis face increased Alzheimer’s risk, study suggests

Published

on

Women with osteoporosis may be more likely to carry a gene linked to Alzheimer’s, according to new research.

Scientists found that APOE4, the most common genetic risk factor for Alzheimer’s, can weaken bone quality in women, even when standard scans appear normal.

The study, carried out by researchers at the Buck Institute for Research on Ageing in California, US, and UC San Francisco, suggests the gene may damage bone at a microscopic level long before any visible signs.

These changes can emerge as early as midlife and remain invisible to routine imaging tests used to assess bone strength.

The findings suggest a link between Alzheimer’s risk and skeletal health and could help pave the way for earlier detection of both conditions.

Professor Birgit Schilling, a senior author of the study, said: “What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch.

“APOE4 is quietly disrupting the very cells responsible for keeping bone strong – and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”

Doctors have long observed that people with Alzheimer’s suffer higher rates of bone fractures, while osteoporosis in women is known to be one of the earliest predictors of the disease.

Now scientists believe they may have uncovered why.

Researchers led by Dr Charles Schurman carried out a detailed analysis of proteins in aged mouse bone and found that tissue was unusually rich in molecules linked to neurological disease, including those associated with Alzheimer’s.

In particular, long-lived bone cells known as osteocytes showed elevated levels of APOE, with levels twice as high in older female mice compared with younger or male animals.

Further experiments using genetically modified mice revealed that APOE4 had a strong and sex-specific impact on both bone and brain tissue.

The disruption at the protein level was even greater in bone than in the brain.

However, the bone structure itself appeared completely normal under scans.

Instead, the gene interfered with a key maintenance process inside bone cells, preventing them from repairing microscopic channels that keep bones strong and resilient.

When this process breaks down, bones become more fragile even if they look healthy on standard imaging.

These results suggest bone cells could potentially act as early biological warning signs of cognitive decline in women carrying APOE4.

Professor Lisa Ellerby, another senior author, said: “We think targeting these cells may open a new front in preserving bone quality in this population.”

Experts say the findings highlight the need to view the body as an interconnected system rather than treating diseases in isolation.

Dementia, of which Alzheimer’s is the most common form, remains one of the UK’s biggest health challenges.

Around 900,000 people are currently living with the condition, a figure expected to rise to 1.6 million by 2040.

It is already the leading cause of death, responsible for more than 74,000 deaths each year.

Continue Reading

News

Relaunched women’s health strategy aims to tackle ‘medical misogyny’

Published

on

Health secretary Wes Streeting has relaunched England’s women’s health strategy, vowing to stop women being “gaslit” by doctors.

Speaking before publication of the renewed strategy, the health secretary said the NHS was “failing women” and set out measures to help them access the healthcare they need.

The government said the strategy would include a new standard of care to ensure women were offered pain relief for invasive procedures, such as fitting a contraceptive coil and hysteroscopies.

Feedback would be directly linked to provider funding through a new trial, giving women more power to affect change if they have a poor experience.

Action would also be taken to ensure women no longer face long waits for diagnoses for conditions such as endometriosis, which can take a decade to diagnose.

Streeting said: “[Women] have for so long been let down by a healthcare system that too often gaslights women, treating their pain as an inconvenience and their symptoms as an overreaction.

“Whether it’s being passed from one appointment to another for conditions like endometriosis and fibroids, or a lack of proper pain relief during invasive procedures, through to having to navigate symptoms for years before receiving a diagnosis, it’s clear the system is failing women.

“Women’s voices must be central to delivering effective, respectful and empathetic care. We need to hit medical misogyny where it hurts – the wallet.

“Today’s renewed strategy will tackle the issues women face every day and ensure no woman is left fighting to be heard.”

A report last month by the women and equalities committee found that gynaecological and menstrual health had not been “sufficiently prioritised” by the government.

MPs said parts of the 10-year women’s health strategy, launched in 2022 by the Conservatives, were at risk of being scaled back or discontinued under wider changes to the NHS.

These included initiatives that had reduced waiting lists and improved women’s access to healthcare, such as women’s health hubs.

Sarah Owen, chair of the committee and a Labour MP, said: “This would be a disaster for girls’ and women’s menstrual healthcare, when it is in dire need of more support.

“It is a national scandal that nearly half a million women are on hospital gynaecology waiting lists when there are effective treatments that could be administered in primary and community care, if only they could access them.”

The report said women faced “medical misogyny” and were left to “suck it up” and suffer in pain for years because of a lack of awareness of women’s health conditions.

A redesign of clinical pathways for some women’s health issues will aim to speed up diagnosis and treatment, and there will be a review of support for families who experience repeated baby loss.

The government also promised a “single referral point” to ensure women were directed to the right place the first time they sought help.

Dr Sue Mann, NHS England’s women’s health director, said too many women were dismissed for “serious symptoms” that affected every part of their lives.

“The renewed women’s health strategy will build significantly on the work the NHS has been doing to ensure women are heard and get the specialist care they need,” she said.

Women’s health groups cautiously welcomed the renewed strategy. Emma Cox, chief executive of Endometriosis UK, said decisive action would be vital to improve women’s healthcare in England.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.